An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

What if a heart attack and lifetime of statin drugs could be avoided with a onetime, two-hour infusion? University of ...

Democrats aren't rushing to play ball with Republicans on a bipartisan health care package after passage of the president's megabill and spending cuts.

Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The ...

As uncertain tariff news continues to dominate Wall Street, Indiana's economy may be impacted. Jane King, a Nasdaq Analyst, says that with the promised rollout of a new round of tariffs on August 1, ...

UnitedHealth Group's pharmacy benefits manager, OptumRx Inc., was hit with an Employee Retirement Income Security Act of 1974 ...